Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

ients have had a maximum Grade 1 QTc interval prolongation, and 7 patients a maximum Grade 2; the increases were clinically asymptomatic and not associated with AEs or dose reduction or delay. One patient who experienced an event of asymptomatic Grade 3 QTc interval prolongation had ineligible baseline QTc values (Grade 2) and was withdrawn from the study. A total of 16 serious AEs were reported in 8 patients. 5 events in 4 patients were considered possibly or probably related to study drug: Grade 3 GI hemorrhage and duodenal ulcer in 1 patient, and Grade 3 pneumonia, Grade 4 pulmonary embolism, and Grade 2 haemoptysis.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor proliferation and vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability (using in vivo systems), demonstrates excellent activity in target-specific cellular functional assays and has shown sustained inhibition of target RTKs preclinically in vivo following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BioPharma Inc. (NASDAQ: ARRY ) today announced ... Pharma AG to acquire worldwide rights to encorafenib (LGX818), ... agreement is conditional on the closing of transactions announced by ... are expected to close in the first half of ...
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... (Nasdaq: VRNM ), a leading developer of cellulosic ... specialty,enzymes, announced today that Carlos A. Riva, President and ... Cowen and Company Clean,Energy Conference. The presentation is scheduled ... 2007 and will take place at Le Parker Meridien ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... CEO will present at the 2007 UBS Global ... Grand Hyatt New York on Wednesday,September 26 at ... A live webcast of the presentation will ...
Cached Biology Technology:Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... were not the only ones with visions of sugar plums ... a new research report published in the January 2010 issue ... ), a team of scientists from the University of Texas ... compound from licorice root (glycyrrhizin from Glycyrrhiza glabra ) ...
... DALLAS Jan. 4, 2010 An experimental drug currently ... fighting the brain cancer glioblastoma and prostate cancer, researchers at ... The drug,s actions, observed in isolated human cells in ... encouraging because they attacked not only the bulk of the ...
... origin of the Devil Facial Tumour Disease (DFTD) that has ... scientists has discovered. Devil Facial Tumour Disease (DFTD) ... was first reported in 1996. It is spread by biting ... large tumours, mostly on the face and mouth, which often ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Experimental drug shows promise against brain, prostate cancers 2Nervous culprit found for Tassie devil facial tumor disease 2
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
Designed for use with any of the Agencourt kits in tube format....
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
Biology Products: